VIEW 1 and VIEW 2 studies: taking a deeper dive
June 30, 2022
Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.
June 30, 2022
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
June 30, 2022
Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.
May 31, 2022
The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
May 28, 2022
Video
Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”
May 27, 2022
Video
As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.
May 12, 2022
Video
At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.